CFZ533 active - Cohort 1 + CFZ533 placebo- Cohort 1 + CFZ533 active - Cohort 2 + CFZ533 placebo - Cohort 2 + CFZ533 active -Cohort 3 + CFZ533 active - Cohort 3
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sjögren's Syndrome
Conditions
Primary Sjögren's Syndrome
Trial Timeline
Oct 22, 2014 → Jun 29, 2018
NCT ID
NCT02291029About CFZ533 active - Cohort 1 + CFZ533 placebo- Cohort 1 + CFZ533 active - Cohort 2 + CFZ533 placebo - Cohort 2 + CFZ533 active -Cohort 3 + CFZ533 active - Cohort 3
CFZ533 active - Cohort 1 + CFZ533 placebo- Cohort 1 + CFZ533 active - Cohort 2 + CFZ533 placebo - Cohort 2 + CFZ533 active -Cohort 3 + CFZ533 active - Cohort 3 is a phase 2 stage product being developed by Novartis for Primary Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02291029. Target conditions include Primary Sjögren's Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sjögren's Syndrome were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02291029 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Sjögren's Syndrome